AKRO
Price
$41.00
Change
+$0.01 (+0.02%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
3.26B
24 days until earnings call
NERV
Price
$1.79
Change
+$0.04 (+2.29%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
12.24M
17 days until earnings call
Ad is loading...

AKRO vs NERV

Header iconAKRO vs NERV Comparison
Open Charts AKRO vs NERVBanner chart's image
Akero Therapeutics
Price$41.00
Change+$0.01 (+0.02%)
Volume$33.16K
Capitalization3.26B
Minerva Neurosciences
Price$1.79
Change+$0.04 (+2.29%)
VolumeN/A
Capitalization12.24M
AKRO vs NERV Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. NERV commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Buy and NERV is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (AKRO: $41.00 vs. NERV: $1.76)
Brand notoriety: AKRO and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 89% vs. NERV: 26%
Market capitalization -- AKRO: $3.26B vs. NERV: $12.24M
AKRO [@Biotechnology] is valued at $3.26B. NERV’s [@Biotechnology] market capitalization is $12.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $276.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, AKRO is a better buy in the long-term than NERV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 4 TA indicator(s) are bullish while NERV’s TA Score has 5 bullish TA indicator(s).

  • AKRO’s TA Score: 4 bullish, 6 bearish.
  • NERV’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NERV is a better buy in the short-term than AKRO.

Price Growth

AKRO (@Biotechnology) experienced а +8.96% price change this week, while NERV (@Biotechnology) price change was +10.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.17%. For the same industry, the average monthly price growth was -3.10%, and the average quarterly price growth was -10.42%.

Reported Earning Dates

AKRO is expected to report earnings on Aug 08, 2025.

NERV is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+8.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($3.26B) has a higher market cap than NERV($12.2M). AKRO YTD gains are higher at: 47.376 vs. NERV (-20.778). NERV has higher annual earnings (EBITDA): 6.02M vs. AKRO (-247.37M). AKRO has more cash in the bank: 743M vs. NERV (21.4M). NERV has less debt than AKRO: NERV (0) vs AKRO (36.5M). AKRO (0) and NERV (0) have equivalent revenues.
AKRONERVAKRO / NERV
Capitalization3.26B12.2M26,754%
EBITDA-247.37M6.02M-4,106%
Gain YTD47.376-20.778-228%
P/E RatioN/A9.21-
Revenue00-
Total Cash743M21.4M3,472%
Total Debt36.5M0-
FUNDAMENTALS RATINGS
AKRO vs NERV: Fundamental Ratings
AKRO
NERV
OUTLOOK RATING
1..100
205
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
58100
SMR RATING
1..100
9199
PRICE GROWTH RATING
1..100
3878
P/E GROWTH RATING
1..100
10044
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (51) in the null industry is in the same range as NERV (56) in the Biotechnology industry. This means that AKRO’s stock grew similarly to NERV’s over the last 12 months.

AKRO's Profit vs Risk Rating (58) in the null industry is somewhat better than the same rating for NERV (100) in the Biotechnology industry. This means that AKRO’s stock grew somewhat faster than NERV’s over the last 12 months.

AKRO's SMR Rating (91) in the null industry is in the same range as NERV (99) in the Biotechnology industry. This means that AKRO’s stock grew similarly to NERV’s over the last 12 months.

AKRO's Price Growth Rating (38) in the null industry is somewhat better than the same rating for NERV (78) in the Biotechnology industry. This means that AKRO’s stock grew somewhat faster than NERV’s over the last 12 months.

NERV's P/E Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for AKRO (100) in the null industry. This means that NERV’s stock grew somewhat faster than AKRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKRONERV
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 18 days ago
84%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ZGFIX18.220.07
+0.39%
American Beacon Ninety One Gbl Frnchs R5
SSCOX5.34N/A
N/A
Touchstone Small Company C
GGIJX13.13N/A
N/A
Goldman Sachs Global Infras R6
COSZX12.12N/A
N/A
Columbia Overseas Value Inst
VSCPX297.71N/A
N/A
Vanguard Small Cap Index InstlPlus

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+0.02%
ETNB - AKRO
59%
Loosely correlated
+0.58%
SLS - AKRO
42%
Loosely correlated
+4.48%
TRDA - AKRO
38%
Loosely correlated
-1.34%
VTYX - AKRO
38%
Loosely correlated
-4.76%
MDGL - AKRO
37%
Loosely correlated
+2.14%
More

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with CVAC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then CVAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
+0.57%
CVAC - NERV
38%
Loosely correlated
-0.92%
GPCR - NERV
37%
Loosely correlated
+0.38%
DNLI - NERV
36%
Loosely correlated
+1.23%
AKRO - NERV
33%
Loosely correlated
+0.02%
ETNB - NERV
33%
Poorly correlated
+0.58%
More